Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.
about
Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Tumour burden at diagnosis as ...... hemotherapy plus radiotherapy.
@en
Tumour burden at diagnosis as ...... hemotherapy plus radiotherapy.
@nl
type
label
Tumour burden at diagnosis as ...... hemotherapy plus radiotherapy.
@en
Tumour burden at diagnosis as ...... hemotherapy plus radiotherapy.
@nl
prefLabel
Tumour burden at diagnosis as ...... hemotherapy plus radiotherapy.
@en
Tumour burden at diagnosis as ...... hemotherapy plus radiotherapy.
@nl
P2093
P2860
P356
P1476
Tumour burden at diagnosis as ...... hemotherapy plus radiotherapy.
@en
P2093
Chiara Coriani
Emilio Bassi
Francesco Merli
Manuela Bergonzi
Massimo Federico
Paolo G Gobbi
P2860
P304
P356
10.1002/HON.2035
P577
2012-10-29T00:00:00Z